Title: | Autoantibodies against type I IFNs in patients with critical influenza pneumonia |
Author: | Zhang, Qian Pizzorno, Andrés Miorin, Lisa Bastard, Paul Gervais, Adrian Le Voyer, Tom Bizien, Lucy Manry, Jeremy Rosain, Jérémie Philippot, Quentin Goavec, Kelian Wroblewski, Isabelle Husebye, Eystein Fellay, Jacques Pothier, Pierre Morand, Patrice Navarrete, Nicolás Franco, José Luis Uddin, Mohammed J. Carratalà, Jordi Merino Díaz, Laura Palomo, Virginia Seppänen, Mikko R.J. Särekannu, Karita Aiuti, Alessandro Retamar Gentil, Pilar Debette, Stéphanie Belot, Alexandre Abel, Laurent Soler Palacín, Pere Abad Arranz, Maria Aguilar Guisado, Manuela Meyts, Isabelle Casanova, Jean-Laurent Gonzalez Granado, Luis L. Butte, Manish J. Itan, Yuval Escoresca Ortega, Ana Morio, Tomohiro Padey, Blandine Niubó, Jordi Gallardo Ríos, Rafaela Lau, Yu-lung Triantafyllia, Vasiliki Briones, Marisa Saker, Kahina Richard, Pascale Drolet, Beth A. Espinosa Padilla, Sara Wauters, Joost Peigue Lafeuille, Helene Valiente, Adoración El Baghdadi, Jamila Tiberghien, Pierre Balsera-manzanero, María Zins, Marie Hammarström, Lennart Andreakos, Evangelos Notarangelo, Luigi D. Debette, Stéphanie Prando, Carolina Condino-neto, Antonio Dominguez Pinilla, Nerea Meyts, Isabelle Aydillo, Teresa Okamoto, Keisuke Soumaré, Aïcha Karamitros, Timokratis Medina, Rafael A. Kisand, Kai Ramírez Duque, Nieves Feys, Simon Romero Oraa, Laura Kuo, Chen-yen Lei, Wei-te Quintana Murci, Lluis Milner, Joshua D. Ku, Cheng-lung Van De Beek, Diederik Hsieh, Elena W.Y. Tal, Galit Fournet, Thomas Cerba Healthcare Group Patural, Hugues Novelli, Giuseppe Lyon Antigrippe Working Group Arias, Andrés A. Rovina, Nikoletta Rodríguez-gallego, Carlos Puel, Anne Jouanguy, Emmanuelle Vinh, Donald C. Abel, Laurent Henny, Joseph Mogensen, Trine H. Cobat, Aurélie Casari, Giorgio Ramaswamy, Sathishkumar Abelenda Alonso, Gabriela Morel, Pascal Trouillet Assant, Sophie Tzourio, Christophe Gallian, Pierre Reipi Inf Working Group García Sastre, Adolfo Constantinescu, Stefan N. Hamzeh Cognasse, Hind Haerynck, Filomeen Flores, Carlos Bousfiha, Ahmed A. García Salum, Tamara Shahrooei, Mohammed Slaby, Ondrej Fragkou, Paraskevi C. Argaud, Laurent Belot, Alexandre Shcherbina, Anna Al-muhsen, Saleh Biggs, Catherine M. Bogunovic, Dusan Planas, Anna M. Heath, James R. Von Bernuth, Horst Dufouil, Carole Bolze, Alexandre Boeuf, Benoit Rodríguez Gallego, Carlos Christodoulou, John Bondarenko, Anastasiia Martin, Fernando Koltsida, Ourania Sediva, Anna Ruiz Hernandez, José Juan Bonneaudeau, Brigitte Cannet, Dorothée Ku, Cheng-lung Etablissement Français Du Sang Study Group Froidure, Antoine Laurent, Emilie Galani, Ioanna Evdokia Gregersen, Peter K. Lemonnier, Sylvie Spaan, András N. Darmon, Michael Grimbacher, Bodo Del Mar Muñoz Garcia, Maria Zawadzki, Pawel Henrickson, Sarah E. Haerynck, Filomeen O'farrelly, Cliona Rosa Calatrava, Manuel Lachaize, Morgane Okada, Satoshi Vanker, Martti Bryceson, Yenan Ling, Yun Cooper, Megan A. Lucas, Carrie L. Maniatis, Tom Romero Vázquez, Gloria María Mansouri, Davood Castagnoli, Riccardo Zins, Marie Maródi, László Mironska, Kristina Rapti, Vasiliki Baris Feldman, Hagit Pozzetto, Bruno Renia, Laurent Tancevski, Ivan Imai, Kohsuke Ozcelik, Tayfun Pan-hammarström, Qiang Al-mulla, Fahd Pape, Jean W. Etzioni, Amos Souweine, Bertrand Perez De Diego, Rebeca Wauters, Joost Sánchez Cordero, Maria Jose Solé Violán, Jordi Perlin, David S. Queromes, Gregory Anderson, Mark S. Resnick, Igor Pesole, Graziano Su, Helen C. Vanderbeke, Lore Hagin, David Jeanne, Michel Desai, Murkesh Ferres, Marcela Sánchez Céspedes, Javier Perroquin, Magali Ng, Lisa F.P. Abou Tayoun, Ahmad Le Corre, Nicole Snow, Andrew L. Temel, Şehime Gülsün Tsiodras, Sotirios Coeuret Pellicer, Mireille Notarangelo, Luigi D. Javouhey, Etienne Turvey, Stuart E. Covid Human Genetic Effort Rombauts, Alexander Zatz, Mayana Uddin, K.m. Furkan Kisand, Kai Fievet, Nathalie Jarvis, Erich D. Rodríguez De Castro, Felipe Ferreres, José Flaig, Amandine Pujol, Aurora Cognasse, Fabrice Sancho Shimizu, Vanessa Tiberghien, Pierre Nadif, Rachel Hanna, Suhair Constances Cohort Goldberg, Marcel Brodin, Petter Andreakos, Evangelos Le Got, Stéphane Ozguler, Anna Quenot, Jean Pierre Novelli, Antonio Cordero, Elisa Colomb, Benoit Cupic, Anastasija Mehlal Sedkaoui, Souad Sallette, Jérôme Hernu, Romain Bustamante, Carlos D. Lina, Bruno Halwani, Rabih Casalegno, Jean Sebastien Schwebel, Carole Salamanca Rivera, Celia 3C-Dijon Study Tangye, Stuart G. Dalgard, Clifton L. |
Keywords: | Grip Pneumònia Autoanticossos Influenza Pneumonia Autoantibodies |
Issue Date: | 16-Sep-2022 |
Publisher: | Rockefeller University Press |
Abstract: | In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old. |
Note: | Reproducció del document publicat a: https://doi.org/10.1084/jem.20220514 |
It is part of: | Journal of Experimental Medicine, 2022, vol. 219, issue. 11 |
URI: | http://hdl.handle.net/2445/191806 |
Related resource: | https://doi.org/10.1084/jem.20220514 |
ISSN: | 1540-9538 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
|